May 2019 Despite being an ‘old’ disease recognized since ancient times, asthma remains a highly prevalent condition around the world and now recognized to be quite heterogeneous in clinical symptoms, severity and outcomes. While new therapies targeting specific inflammatory pathways have become available in the last few years, not all patients qualify or will benefit from them. At its root, the underlying drivers of asthma remain not well understood, are likely multifactorial